Volume 16, Number 12—December 2010
CME ACTIVITY - Dispatch
Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus, South Korea
Table 1
Characteristics of 10 patients infected with oseltamivir-resistant pandemic (H1N1) 2009 virus, South Korea, 2009
Patient | Age, y/ sex | Antiviral treatment and date | Date of specimen collection | Type of clinical specimen | Underlying condition |
---|---|---|---|---|---|
A | 5/M | Oseltamivir, 30 mg 2×/d (Oct 29–Nov 4); 60 mg 2×/d (Nov 5–9) | Nov 6 | Nasopharyngeal swab | Mitochondrial cytopathic changes (bedridden) |
B | 46/M | Oseltamivir, 150 mg 2×/d (Nov 6–15); zanamivir, 10 mg 2×/d (Nov 16–26) | Nov 18 | Nasopharyngeal swab | Leukemia |
C | 1/F | Oseltamivir, 30 mg 2×/d (Nov 16–21); 60 mg 2×/d (Nov 22–Dec 8) | Nov 21 and 22 | Nasopharyngeal swab | Brain damage (fatal) |
D | 2/M | Oseltamivir, 90 mg 2×/d (Nov 26–30); 180 mg and amantadine, 65 mg 2×/d (Dec 2–7) | Nov 22, Dec 2 | Nasal suction | None |
E | 3/F | Oseltamivir, 30 mg 2×/d (Dec 1–5 and 7–11) | Dec 1, 7, and 9 | Oropharyngeal swab (Dec 1, 7); nasopharyngeal swab (Dec 9) | Asthma |
F | 3/F | Oseltamivir, 45 mg 2×/d (Dec 10–15); 75 mg 2×/d (Dec 16–20) | Dec 18 | Oropharyngeal swab | Delayed development |
G | 1/F | Oseltamivir, 30 mg 2×/d (Dec 1–5); peramivir, 75 mg 1×/day (Dec 12–18) | Dec 1, 5, and 15 | Nasal/oropharyngeal swab | Myelodysplasia (fatal) |
H | 63/M | Oseltamivir, 150 mg 2×/d (Dec 7–15); zanamivir, 10 mg 2×/d (Dec 16–20) | Dec 16 | Oropharyngeal swab | Diabetes |
I | 58/M | Oseltamivir, 150 mg 2×/d (Dec 16–18); peramivir, 600 mg 1×/d, amantadine, 100 mg 2×/d a day, ribavirin, 300 mg 1×/d (Dec 19–25); zanamivir, 10 mg 2×/d (Dec 26–2010 Jan 1) | Dec 26 | Nasopharyngeal swab | Cancer |
J | 60/M | Oseltamivir, 75 mg 2×/d (Nov 30–Dec 2) | Dec 1 | Viral RNA | Diabetes, cardiac disorders (fatal) |